We hope you had a terrific Thanksgiving, everyone! As the holidays ramp up, pause a moment and catch up on the useful content we brought you this fall. This includes a broad survey of the latest digital concussion tools, highlights from the recent annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), and new guidelines from the American Epilepsy Society. Enjoy!
Even though the big Zika outbreak came to a close at the end of 2016, the fallout isn’t over. Because of the nature of the disease, it is reasonable to assume that neurologists will be major players as the full consequences of the outbreak become clear. In August, the CDC published new information about the effect of Zika on children born to infected women. READ MORE >
For this two-part series, we interviewed Jose Posas, MD, a neurologist with the Concussion Management Program at Ochsner Health System in New Orleans. He gives his recommendations for navigating the ever-expanding world of digital concussion apps and data collection systems. Don’t worry, if you are completely new to this, he has advice for you too. READ MORE >
Decision-making can be difficult for patients with epilepsy who struggle with the looming risk of seizure. So it’s natural that you want to remove any uncertainty about treatment you can, helping these patients maintain as much control over this aspect of their lives as possible. As their neurologist, your knowledge is a tool that can help them navigate uncertainty. When patients find themselves needing to make treatment decisions without their trusted doctor, Choosing Wisely® can offer much-needed clarity. READ MORE >
The question of who should be having the informed consent discussion with the patient recently got a little more complicated. At the recent annual meeting of the AANEM, Segun Toyin Dawodu, MD, JD, led a lively discussion on a pivotal court case, Shinal v. Toms. Dawodu focused on the existing requirements for informed consent and how the Pennsylvania supreme court case might impact them. READ MORE >
Both emotion and politics can stand in the way of an objective look at drug-pricing, preventing collaboration to find solutions. It is important that any pricing model be designed to achieve the goal of sustainable access to high-value care for all patients. Long-term value and short-term affordability are required to achieve this goal, says Dr. Steven Pearson, who addressed this issue at the recent AANEM meeting. READ MORE >